Expanding the design space of protein-small molecule conjugates

扩大蛋白质-小分子缀合物的设计空间

• 批准号: 10729980
• 负责人: Sarah J. Moore
• 金额: $ 39.88万
• 依托单位: SMITH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10729980
• 关键词: Alkynes; Amino Acids; Antibody-drug conjugates; Azides; Binding; Biological; Biotechnology; Caring; Cell model; Cells; Chemicals; Chemistry; Clinical; Combined Modality Therapy; Complex; Coupled; Cysteine; Data; Diagnosis; Directed Molecular Evolution; Disease; Drug Delivery Systems; Drug Targeting; Drug Transport; Engineering; Future; Goals; Hematologic Neoplasms; Immune System Diseases; In Vitro; Kinetics; Libraries; Location; Malignant Neoplasms; Measures; Medical; Medicine; Methods; Minority; Modeling; Molecular; Molecular Target; Oncology; Outcome; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Physiological; Polymers; Production; Property; Protein Biosynthesis; Proteins; Radial; Reaction; Reporting; Research; Scaffolding Protein; Site; Solid Neoplasm; Structure; Sulfhydryl Compounds; System; Therapeutic; Tissues; Translating; Variant; Work; cancer therapy; clinical care; design; experimental study; fluorophore; improved outcome; in vivo; molecular recognition; nervous system disorder; novel; polypeptide; precision medicine; scaffold; side effect; small molecule; success; targeted treatment; trafficking

PROJECT SUMMARY/ABSTRACT Targeted therapy and targeted drug delivery have revolutionized clinical care of complex disease whenever these options are available – and, yet, only a minority of patients have access to these precision medicine approaches where their care is based on the molecular basis of their disease. Such molecular targeting leads to better patient outcomes and fewer toxic side effects compared to traditional treatment approaches, for a range of diseases. As part of expanding precision medicine to all patients with complex diseases, there is a critical need to meet the molecular targeting gaps in clinical care where such options currently do not exist. Protein- drug conjugates have immense promise in targeted therapy and drug delivery applications, with a number of recent successes in the form of antibody-drug conjugates (ADCs) for cancer therapy. However, numerous design challenges for protein-drug conjugates remain, including narrow therapeutic windows and difficulty in translating success in oncology to other clinical indications. Even within oncology, solid tumors remain significantly more difficult to treat than hematological cancers. Our hypothesis is that the current set of modular components in the design space is limiting and leads to many of the current challenges. Therefore, there is an unmet need to create and validate protein-drug conjugate components and combinations beyond those currently being used. The overall goal of this proposed research is to expand the design space for protein-drug conjugates, enabling this class of molecules to have further success in a wider range of applications in biotechnology and medicine. We propose to validate scaffold proteins and side-chain reactive polymers as modular components for novel protein-drug conjugate structures. As a model protein scaffold for this work, we will use the Fn3 polypeptide fold, which has been demonstrated to be extremely versatile for engineering molecular recognition using rational and directed evolution approaches. We propose to modify model Fn3 proteins with canonical and non-canonical amino acids to enable site-specific bioconjugation reactions (Aim 1). As a novel linker system for protein-drug conjugates, we propose to use side-chain reactive poly(PFPA), as a model polymer for synthesizing protein- polymer-drug conjugates. Side-chain reactive polymers are more chemically versatile than current linkers in use for ADCs, and can serve multiple functions to overcome current ADC limitations. We will functionalize polymer poly(PFPA) to enable conjugation to specific protein sites, and load releasable small molecules onto the polymer, using a range of drug loading ratios, with combinations of small molecules to enable combination therapy (Aim 2). We will measure and model cellular and tissue trafficking of the conjugates (Aim 3), a key consideration for therapeutic success. The overall objective of this application is to extend the capacity of scaffold proteins and side-chain reactive polymers to fill the gap in molecular targeting challenges. Our work will have a broader positive impact by establishing methods for synthesizing bioconjugates using a myriad of polypeptide folds and polymer linkers, towards the ultimate goal of creating targeted treatments for every patient who needs them.

项目总结/文摘